• linkedin
  • Increase Font
  • Sharebar

    A promising target for immunotherapy?

     

    Patient-derived xenografts from primary and metastatic prostate cancer lesions are being used to interrogate biology underlying development of resistance and to suggest alternative therapeutic approaches.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results